SCHEMBL8058862

SCHEMBL8058862

NCCCNCCCC(NCCCN)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGT1 P19440 2/20 0.50
FOLH1 Q04609 1/20 0.44
CASP2 P42575 2/20 0.43
CA12 O43570 2/20 0.43
F13A1 P00488 2/20 0.43
CA2 P00918 2/20 0.43
CYP1A2 P05177 2/20 0.43
ALOX15 P16050 2/20 0.43
CA4 P22748 2/20 0.43
CA6 P23280 2/20 0.43
CA5A P35218 2/20 0.43
THPO P40225 2/20 0.43
CA7 P43166 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
CA5B Q9Y2D0 2/20 0.43
MEN1 O00255 1/20 0.43
CYP2C19 P33261 1/20 0.43
RECQL P46063 1/20 0.43
KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890284 0.90 GGT1 (0.55) GGT1FOLH1NOD1GSR
SCHEMBL146727 0.90 GGT1 (0.55) GGT1FOLH1NOD1GSR
SCHEMBL6316197 0.89 FOLH1 (0.54) GGT1FOLH1CA2CA1NOD1
SCHEMBL6859366 0.89 FOLH1 (0.54) GGT1FOLH1CA2CA1NOD1
SCHEMBL12951159 0.86 SIRT6 (0.46)
SCHEMBL12085468 0.86 SIRT6 (0.42) CASP2CA12F13A1CA2CYP1A2
SCHEMBL19732599 0.85 CA12 (0.43) GGT1CASP2CA12F13A1CA2
SCHEMBL7076576 0.85 FOLH1 (0.54) GGT1FOLH1CA2PAOXCA1
SCHEMBL148480 0.85 FOLH1 (0.54) GGT1FOLH1CA2PAOXCA1
SCHEMBL12085570 0.84 SIRT6 (0.48) CASP2CA12F13A1CA2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3766981-A1 CATIONIC POLOXAMERS AND THEIR USE IN TRANSDUCTION OZ Biosciences (FR) 2021-01-20 EP disclosed
US-10434186-B2 Functionalized linear ligands and complexes thereof LUMIPHORE, INC. (US) 2019-10-08 US disclosed
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. 2017-12-21 US disclosed
WO-2016106241-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF LUMIPHORE, INC. (US) 2016-06-30 WO disclosed
US-6107286-A COMPLEXING WITH NUCLEIC ACIDS RHONE-POULENC RORER S.A. (FR) 2000-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360956-A1 FUNCTIONALIZED LINEAR LIGANDS AND COMPLEXES THEREOF CLTB, CLTA, EPCAM GGT1 1670/4885FOLH1 196/4885CASP2 3804/4885
US-10434186-B2 Functionalized linear ligands and complexes thereof CLTB, CLTA, EPCAM GGT1 1670/4885FOLH1 196/4885CASP2 3804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.